Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin.

Few compounds but apcin have previously been reported as Cdc20 specific inhibitor, although Cdc20 is a very promising drug target. We reported here the design, synthesis, and biological evaluations of 2,2,2-trichloro-1-aryl carbamate derivatives as Cdc20 inhibitors. Among these derivatives, compound 9f was much more efficient than the positive compound apcin in inhibiting cancer cell growth, but it had approximately the same binding affinity with apcin in SPR assay, the assumption that other mechanisms of action might exist was feasible. Consistently, further evidences demonstrated that compound 9f also inhibited tubulin polymerization and disorganized microtubule, blocked cell cycle arrest in M phase with the alteration in the expression of cyclins, thus induced apoptosis through the activation of caspase-3 and PARP. In addition, compound 9f inhibited cell migration and invasion in a concentration-dependent manner. These results supported further guidance for developing the current series as potential new anticancer therapeutics.

[1]  K. Strebhardt,et al.  Boosting the apoptotic response of high‐grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro‐survival protein MCL‐1 , 2020, International journal of cancer.

[2]  A. Kamal,et al.  Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018) , 2019, Expert opinion on therapeutic patents.

[3]  F. Rödel,et al.  Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability , 2019, Neoplasia.

[4]  M. Steinmetz,et al.  Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure. , 2018, Journal of medicinal chemistry.

[5]  Xu Ma,et al.  Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells , 2018, Cell cycle.

[6]  Yu Cao,et al.  Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition , 2017, Cell cycle.

[7]  Zhong-Zhen Zhou,et al.  Discovery of 9H-purins as potential tubulin polymerization inhibitors: Synthesis, biological evaluation and structure-activity relationships. , 2017, European journal of medicinal chemistry.

[8]  Honghao Sun,et al.  Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. , 2017, Future medicinal chemistry.

[9]  Diego Bonatto,et al.  Anti‐mitotic agents: Are they emerging molecules for cancer treatment?☆ , 2017, Pharmacology & therapeutics.

[10]  Yan-wei Liu,et al.  CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression , 2017, Journal of Neuro-Oncology.

[11]  V. Bolanos-Garcia,et al.  Cdc20: At the Crossroads between Chromosome Segregation and Mitotic Exit. , 2017, Trends in biochemical sciences.

[12]  Yu Zhang,et al.  Inhibition of Cell Survival by Curcumin Is Associated with Downregulation of Cell Division Cycle 20 (Cdc20) in Pancreatic Cancer Cells , 2017, Nutrients.

[13]  Norman E. Davey,et al.  Building a Regulatory Network with Short Linear Sequence Motifs: Lessons from the Degrons of the Anaphase-Promoting Complex. , 2016, Molecular cell.

[14]  F. Liu,et al.  Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site , 2016, Molecules.

[15]  Mingjing He,et al.  Insights into APC/C: from cellular function to diseases and therapeutics , 2016, Cell Division.

[16]  Zhiwei Wang,et al.  Targeting Cdc20 as a novel cancer therapeutic strategy. , 2015, Pharmacology & therapeutics.

[17]  A. Oda,et al.  Development of a novel class of tubulin inhibitor from desmosdumotin B with a hydroxylated bicyclic B-ring. , 2015, Journal of medicinal chemistry.

[18]  Sushama Sivakumar,et al.  Spatiotemporal regulation of the anaphase-promoting complex in mitosis , 2015, Nature Reviews Molecular Cell Biology.

[19]  Gurneet Kaur,et al.  Recent developments in tubulin polymerization inhibitors: An overview. , 2014, European journal of medicinal chemistry.

[20]  Kumar Singha Roy,et al.  Withaferin A modulates the Spindle assembly checkpoint by degradation of Mad2-Cdc20 complex in colorectal cancer cell lines. , 2014, Biochemical pharmacology.

[21]  Timothy B Sackton,et al.  Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C , 2014, Nature.

[22]  A. Letai,et al.  APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. , 2014, Developmental cell.

[23]  P Kronqvist,et al.  Cdc20 and securin overexpression predict short-term breast cancer survival , 2014, British Journal of Cancer.

[24]  S. Bondock,et al.  Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives. , 2014, European journal of medicinal chemistry.

[25]  Jinfang Zhang,et al.  Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. , 2014, Biochimica et biophysica acta.

[26]  Long Bai,et al.  CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer , 2013, Journal of Translational Medicine.

[27]  Zhiwei Wang,et al.  Cdc20: a potential novel therapeutic target for cancer treatment. , 2013, Current pharmaceutical design.

[28]  C. Gridelli,et al.  Emerging mitotic inhibitors for non-small cell carcinoma , 2013, Expert opinion on emerging drugs.

[29]  G. Sandusky,et al.  NAHA, a Novel Hydroxamic Acid-Derivative, Inhibits Growth and Angiogenesis of Breast Cancer In Vitro and In Vivo , 2012, PloS one.

[30]  M. Malumbres,et al.  Killing cells by targeting mitosis , 2012, Cell Death and Differentiation.

[31]  D. Sliva,et al.  Ganodermanontriol (GDNT) exerts its effect on growth and invasiveness of breast cancer cells through the down-regulation of CDC20 and uPA. , 2011, Biochemical and biophysical research communications.

[32]  J. G. Teodoro,et al.  Targeting the anaphase promoting complex: common pathways for viral infection and cancer therapy , 2011, Expert opinion on therapeutic targets.

[33]  D. Oh,et al.  Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. , 2010, Cancer cell.

[34]  T. Fujita,et al.  APC/C-Cdh1 , 2010, Cell cycle.

[35]  Yong Wan,et al.  An in vivo study of Cdh1/APC in breast cancer formation , 2009, International journal of cancer.

[36]  Hans Lehrach,et al.  The molecular basis of genistein-induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines , 2008, BMC Medical Genomics.

[37]  Duane D. Miller,et al.  Structure guided design, synthesis, and biological evaluation of 2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) analogs targeting the colchicine binding site in tubulin. , 2019, Journal of medicinal chemistry.

[38]  M. Pagano,et al.  The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer. , 2014, Biochimica et biophysica acta.